References
- Arshad U, Ploylearmsaeng SA, Karlsson MO, Doroshyenko O, Langer D, Schömig E, Kunze S, Güner SA, Skripnichenko R, Ullah S, et al. 2020. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. Cancer Chemother Pharmacol. 85(4):711–722.
- Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, et al. 2019. Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther. 105(3):598–613.
- Common Terminology Criteria for Adverse Events (CTCAE v5.0). 2017; [accessed 2022 May 21]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Friberg LE, Freijs A, Sandström M, Karlsson MO. 2000. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther. 295(2):734–740.
- Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, et al. 2016. Adjuvant Oral Uracil-Tegafur with Leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS One. 11(9):e0162400.
- Inoue S, Ohtani H, Tsujimoto M, Hori S, Sawada Y. 2007. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. Drug Metab Pharmacokinet. 22(3):162–168.
- Kobuchi S, Ito Y, Hayakawa T, Kuwano S, Baba A, Shinohara K, Nishimura A, Shibata N, Takada K. 2014. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats. Xenobiotica. 44(9):804–818.
- Kobuchi S, Ito Y, Takamatsu D, Sakaeda T. 2018. Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. Eur J Pharm Sci. 123:452–458.
- Kobuchi S, Ito Y. 2020. Application of pharmacometrics of 5-fluorouracil to personalized medicine: a tool for predicting pharmacokinetic-pharmacodynamic/toxicodynamic responses. Anticancer Res. 40(12):6585–6597.
- Kobuchi S, Katsuyama Y, Ito Y. 2020. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats. Xenobiotica. 50(2):223–230.
- Kobuchi S, Tsuda M, Okamura M, Nakamura T, Ito Y. 2022. Pharmacokinetic-pharmacodynamic Model Predicts Uracil-tegafur effect on tumor shrinkage and myelosuppression in a colorectal cancer rat model. Anticancer Res. In press.
- Kosugi C, Koda K, Takiguchi N, Takaishi S, Miyauchi H, Hirayama N, Nomura Y, Kondo E, Kawasaki Y, Ozawa Y, et al. 2021. Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial). Int J Colorectal Dis. 36(8):1739–1749.
- Miyake Y, Nishimura J, Kato T, Ikeda M, Tsujie M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, et al. 2018. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surg Today. 48(1):66–72.
- Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 17:e38.
- Shiraiwa K, Suzuki Y, Uchida H, Iwashita Y, Tanaka R, Iwao M, Tada K, Hirashita T, Masuda T, Endo Y, et al. 2021. Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. Sci Rep. 11(1):3132.
- Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O'Dwyer PJ, Muro K, Yamada Y, et al. 2004. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 22(17):3466–3474.
- Tada K, Iwashita Y, Shiraiwa K, Uchida H, Oshima Y, Sato Y, Nakanuma H, Hirashita T, Masuda T, Endo Y, et al. 2020. Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model. Cancer Chemother Pharmacol. 85(2):345–352.